Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 1

1	Impact of intraoperative use of venovenous
2	extracorporeal membrane oxygenation on the status of
3	von Willebrand factor large multimers during single
4	lung transplantation
5	
6	Hisashi Oishi <sup>1*</sup> , Yoshinori Okada <sup>1</sup> , Yamato Suzuki <sup>1</sup> , Takashi Hirama <sup>1</sup> , Yutaka Ejima <sup>2</sup> , Shin-ichi
7	Fujimaki <sup>3</sup> , Shingo Sugawara <sup>3</sup> , Noriyuki Okubo <sup>3</sup> , Hisanori Horiuchi <sup>4</sup>
8	
9	<sup>1</sup> Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku
10	University, Sendai, Japan
11	<sup>2</sup> Department of Anesthesiology, Tohoku University Hospital, Sendai, Japan
12	<sup>3</sup> Department of Laboratory Medicine, Tohoku University School of Medicine, Sendai, Japan
13	<sup>4</sup> Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer,
14	Tohoku University, Sendai, Japan
15	
16	* Corresponding author
17	Email: hisashi.oishi.c7@tohoku.ac.jp (HO)
18	
19	Trial registration:
20	UMIN Clinical Trials Registry (UMIN-CTR), UMIN000018135
21	

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 2

## 22 Abstract

## 23 **Purpose**

24	von Willebrand factors (vWFs), hemostatic factors, are produced as large multimers and
25	are shear stress-dependently cleaved to become the appropriate size. A reduction in vWF large
26	multimers develops in various conditions including the use of extracorporeal life support, which
27	can cause excessive-high shear stress in the blood flow and result in hemostatic disorders. The
28	objective of this prospective study was to investigate the impact of venovenous extracorporeal
29	membrane oxygenation (VV ECMO) use on the status of vWF large multimers and hemostatic
30	disorders during single lung transplantation (SLT).
31	Methods
32	We prospectively enrolled 12 patients who underwent SLT at our center. Among them,
33	seven patients were supported by VV ECMO intraoperatively (ECMO group) and the remaining
34	five patients underwent SLT without ECMO support (control group). The vWF large multimer
35	index (%) was defined as the ratio of the large multimer proportion in total vWF (vWF large
36	multimer ratio) derived from a patient's plasma to that from the standard human plasma.
37	Results
38	The vWF large multimer index at the end of the surgery was significantly lower in the
39	ECMO group than in the control group (112.6% vs. 75.8%, respectively; $p < 0.05$ ). The
40	intraoperative blood loss and the amounts of intraoperative transfusion products in the ECMO
41	group tended to be greater than those in the control group; however, the differences were not

42 significant.

## 43 Conclusion

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 3

#### 44 During SLT, the intraoperative use of VV ECMO caused a decrease in the vWF large

- 45 multimer index. However, the vWF large multimer index was maintained at > 75% in average at
- 46 the end of SLT, which did not affect the bleeding complications.

47

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 4

## 48 Introduction

70

49	One of the most severe complications in lung transplantation is perioperative blood loss.
50	Large-volume transfusions of red blood cells (RBCs) and platelets have been reported to be
51	associated with various complications in lung transplant recipients in multiple studies [1].
52	Diamond et al. have identified large-volume RBC transfusion (> 1 L) as a risk factor for grade 3
53	primary graft dysfunction (PGD) in a prospective, multicenter cohort study [2]. Platelet
54	transfusions were shown to be substantial risk factors for the production of anti-human leukocyte
55	antigen (HLA) antibodies [3], which have a potential to cause chronic lung allograft dysfunction
56	(CLAD)[4].
57	
58	Intraoperative use of extracorporeal life support (ECLS) is one of the risk factors for the
59	increased amount of bleeding and transfusion in lung transplantation. Among ECLSs,
60	cardiopulmonary bypass (CPB) had been reported to increase blood transfusion due to
61	coagulopathy and inflammatory response [5]. Currently, venoarterial extracorporeal membrane
62	oxygenation (VA ECMO), which is associated with lower blood loss during lung transplant
63	surgeries compared with CPB [6], is preferably used for lung transplant cases unless intracardiac
64	repairs are required [7]. Moreover, venovenous (VV) ECMO has been used as an intraoperative
65	extracorporeal mechanical support for lung transplantation at some lung transplant centers in
66	recent years [8]. We started utilizing VV ECMO in 2015 and reported that VV ECMO could be a
67	choice for intraoperative extracorporeal mechanical support during single lung transplantation
68	(SLT) [9].
69	

Although the increase in the amount of bleeding during ECLS is primarily due to the use

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 5

71	of heparin, recent studies have suggested the involvement of acquired von Willebrand syndrome
72	(AvWS), which is one of the hemostatic disorders. von Willebrand factor (vWF) is a hemostatic
73	factor that is produced and secreted as large multimers by endothelial cells and megakaryocytes.
74	vWF initially forms a huge multimer and is then shear stress-dependently cleaved in the
75	bloodstream by its specific cleaving enzyme ADAMTS13, and then is present as multimers
76	consisting of $2 - 80$ vWF monomers [10,11]. The conformation change of A2 domain of vWF by
77	shear stress in the blood flow triggers its cleavage by ADAMTS13. Among the vWF multimers,
78	higher molecular weight multimers (large multimers) are known to play a critical role in
79	hemostasis [10,11]. Lack of ADAMTS13 results in excessive platelet thrombus formation by the
80	function of ultra-large vWF multimers, as seen in patients with hereditary thrombotic
81	thrombocytopenic purpura [12]. On the other hand, some genetic mutations in the vWF A2
82	domain cause a reduction in large multimers and induce a hemostatic disorder by increasing the
83	susceptibility of vWF to cleavage by ADAMTS13 [11]. A reduction in vWF large multimers
84	develops in various other conditions including cardiovascular diseases such as aortic stenosis and
85	the use of ECLS, which can cause excessive-high shear stress in the blood flow and result in
86	hemostatic disorders [11]. This hemostatic disorder caused by excessive cleavage of vWF is
87	defined as AvWS [13].

88

Kalbhenn et al. reported that patients treated with VV ECMO support developed AvWS
[14]. They have shown that using VV ECMO for pneumonia, ARDS, and so forth can cause
unphysiologically high shear stress in the blood stream leading to AvWS within 24 hours after
ECMO exposure [14]. However, it remains unclear whether VV ECMO use in a short period of
time during lung transplant surgery can causes a decrease of vWF large multimers. The objective
of this prospective study was to investigate the impact of VV ECMO use on the status of vWF

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 6

- 95 large multimers and hemostatic disorders during SLT.
- 96

## 97 Patients and Methods

#### 98 Patients, blood sample and data collection, and study groups

The Ethics Committee of Tohoku University Graduate School of Medicine approved this retrospective study (IRB approval number, 2016-1-629; protocol number, UMIN000018135), and written informed consent was obtained from all participants. We prospectively enrolled 12 patients who would undergo SLT under VV ECMO or without ECMO at Tohoku University Hospital from April 2017 to December 2019 (participant recruitment start date, January 10, 2017; last follow-up date, December 31, 2020) (Fig. 1). The study was carried out in compliance with the 2000 Declaration of Helsinki and its later amendments.

106

For the analysis of ADAMTS13 activity and vWF large multimers, blood samples were 107 108 collected in a tube containing 3.2% sodium citrate from the patients immediately before lung 109 transplantation, before reperfusion (immediately before reperfusion of the lung graft), and at the 110 end of surgery. The plasma of the collected blood was stored at - 80 °C until analysis. The 111 collected data were as follows: pretransplant demographics of the recipients, operative 112 characteristics, postoperative characteristics, and mortality. The level of the pleural adhesion was 113 assessed intraoperatively and graded as follows according to the area of adhesion: severe, 50% to 114 whole thoracic cavity; moderate, partial (only band adhesions) to < 50%; mild, no to partial 115 adhesion; none, no adhesion.

116

### 117 **ECMO induction procedure and intraoperative management**

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 7

118	We established VV ECMO by using right and left femoral veins for the cannulation
119	sites. For the inflow, a 15–22 Fr cannula (CAPIOX EBS, Terumo Corp., Tokyo, Japan or HLS
120	Cannulae, Getinge Group Japan K.K., Tokyo, Japan) was inserted, and the tip was adjusted
121	within a caudal part of the inferior vena cava to minimize the recirculation. For the outflow, a 15-
122	21 Fr cannula (CAPIOX EBS, Terumo Corp., Tokyo, Japan or HLS Cannulae, Bio-Medicus,
123	Medtronic Japan Co., Ltd., Tokyo, Japan) was inserted and the tip was placed at the right atrium
124	using transesophageal echocardiography guidance. The blood flow rate of VV ECMO was started
125	at 50% of the estimated cardiac output of the recipient and adjusted according to the
126	intraoperative results of the arterial blood gas analysis ( $1.5 - 2.5$ L/min). Heparin administration
127	was controlled to target the activated clotting time (ACT) from $160 - 180$ s.
128	
129	Measurement of ADAMTS13 activity and quantitative method for
130	calculation of the vWF large multimer index
130 131	<i>calculation of the vWF large multimer index</i> ADAMTS13 activity was measured based on the FRETS-VWF73 assay by SRL Co.
130 131 132	<i>calculation of the vWF large multimer index</i> ADAMTS13 activity was measured based on the FRETS-VWF73 assay by SRL Co. (Tokyo, Japan) [15]. We first determined the concentrations of vWF antigen (vWF:Ag) in the
130 131 132 133	<i>calculation of the vWF large multimer index</i> ADAMTS13 activity was measured based on the FRETS-VWF73 assay by SRL Co. (Tokyo, Japan) [15]. We first determined the concentrations of vWF antigen (vWF:Ag) in the standard human plasma (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany)
130 131 132 133 134	<i>calculation of the vWF large multimer index</i> ADAMTS13 activity was measured based on the FRETS-VWF73 assay by SRL Co. (Tokyo, Japan) [15]. We first determined the concentrations of vWF antigen (vWF:Ag) in the standard human plasma (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany) by quantitative immunoelectrophoresis using an automatic analyzer. Then, the same amount of
<ol> <li>130</li> <li>131</li> <li>132</li> <li>133</li> <li>134</li> <li>135</li> </ol>	calculation of the vWF large multimer index         ADAMTS13 activity was measured based on the FRETS-VWF73 assay by SRL Co.         (Tokyo, Japan) [15]. We first determined the concentrations of vWF antigen (vWF:Ag) in the         standard human plasma (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany)         by quantitative immunoelectrophoresis using an automatic analyzer. Then, the same amount of         vWF:Ag in the plasma of each sample and that in the standard human plasma were analyzed side-
<ol> <li>130</li> <li>131</li> <li>132</li> <li>133</li> <li>134</li> <li>135</li> <li>136</li> </ol>	<i>calculation of the vWF large multimer index</i> ADAMTS13 activity was measured based on the FRETS-VWF73 assay by SRL Co. (Tokyo, Japan) [15]. We first determined the concentrations of vWF antigen (vWF:Ag) in the standard human plasma (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany) by quantitative immunoelectrophoresis using an automatic analyzer. Then, the same amount of vWF:Ag in the plasma of each sample and that in the standard human plasma were analyzed side- by-side by the so-called vWF multimer analysis, which is a western blot analysis under non-
<ol> <li>130</li> <li>131</li> <li>132</li> <li>133</li> <li>134</li> <li>135</li> <li>136</li> <li>137</li> </ol>	calculation of the vWF large multimer index         ADAMTS13 activity was measured based on the FRETS-VWF73 assay by SRL Co.         (Tokyo, Japan) [15]. We first determined the concentrations of vWF antigen (vWF:Ag) in the         standard human plasma (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany)         by quantitative immunoelectrophoresis using an automatic analyzer. Then, the same amount of         vWF:Ag in the plasma of each sample and that in the standard human plasma were analyzed side-         by-side by the so-called vWF multimer analysis, which is a western blot analysis under non-         reduced conditions. The bands of the 11th and those over the 11th were defined as large
<ol> <li>130</li> <li>131</li> <li>132</li> <li>133</li> <li>134</li> <li>135</li> <li>136</li> <li>137</li> <li>138</li> </ol>	calculation of the vWF large multimer index ADAMTS13 activity was measured based on the FRETS-VWF73 assay by SRL Co. (Tokyo, Japan) [15]. We first determined the concentrations of vWF antigen (vWF:Ag) in the standard human plasma (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany) by quantitative immunoelectrophoresis using an automatic analyzer. Then, the same amount of vWF:Ag in the plasma of each sample and that in the standard human plasma were analyzed side- by-side by the so-called vWF multimer analysis, which is a western blot analysis under non- reduced conditions. The bands of the 11th and those over the 11th were defined as large multimers. The vWF large multimer proportion was calculated as the densitometric area of those
<ol> <li>130</li> <li>131</li> <li>132</li> <li>133</li> <li>134</li> <li>135</li> <li>136</li> <li>137</li> <li>138</li> <li>139</li> </ol>	<b>calculation of the vWF large multimer index</b> ADAMTS13 activity was measured based on the FRETS-VWF73 assay by SRL Co. (Tokyo, Japan) [15]. We first determined the concentrations of vWF antigen (vWF:Ag) in the standard human plasma (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany) by quantitative immunoelectrophoresis using an automatic analyzer. Then, the same amount of vWF:Ag in the plasma of each sample and that in the standard human plasma were analyzed side- by-side by the so-called vWF multimer analysis, which is a western blot analysis under non- reduced conditions. The bands of the 11th and those over the 11th were defined as large multimers. The vWF large multimer proportion was calculated as the densitometric area of those bands using Image J (National Institutes of Health, Bethesda, MD). Then, we determined the

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 8

multimer index (%) was defined as the ratio of the large multimer proportion in the total vWF
(vWF large multimer ratio) derived from a sample to that from the standard human plasma in the
adjacent lane [16,17] (Fig. 2). Thus, a patient's vWF large multimer index was expressed as a
ratio (percentage) of the standard.

145

#### 146 Statistical Analysis

147 Continuous data are expressed as group mean  $\pm$  standard error with ranges. Categorical 148 variables are presented as numbers and percentages. For comparison between the groups, 149 Student's or Welch's t-test was used for the parametric data. Mann-Whitney U test was used for 150 the nonparametric data. Fisher's exact test or the chi-square test was performed for the 151 categorical values. The ADAMTS13 activity, vWF:Ag, and vWF large multimer index at each 152 time point were analyzed by repeated measures two-way ANOVA. Differences were considered 153 significant at the p < 0.05 level. Statistical analyses were performed using Prism 5 (GraphPad 154 Software Inc, La Jolla, Calif) and SPSS Statistics 21.0 for Windows (IBM Corporation, Chicago, 155 IL, USA).

156

### 157 **Results**

### 158 Study groups and pre-transplant demographics of the recipients

All enrolled patients were followed up until one year after lung transplantation at Tohoku University Hospital, except for one 90-day mortality case. In the present study, we analyzed 5 SLT cases without ECMO use and 7 SLT cases with VV ECMO use. Table 1 shows the pretransplant demographics of the recipients. Recipient age, gender, height, weight, and body

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 9

163	mass index (BMI) were similar between the 2 groups. Forced vital capacity (FVC) was
164	comparable between the groups. Because the control group included 3 cases of chronic
165	obstructive pulmonary (COPD), forced expiratory volume in one second (FEV1) in the control
166	group tended to be lower than that in the ECMO group; however, the difference was not
167	statistically significant. There was no significant difference between the 2 groups in prothrombin
168	time-international normalized ratio (PT-INR), activated partial thromboplastin time (APTT), or
169	platelet count.

170

#### 171 **Operative characteristics**

Table 2 shows the operative characteristics. There was no significant difference in the 172 operative and cold ischemic time (CIT) between the 2 groups. The mean intraoperative ECMO 173 174 time in the ECMO group was  $487 \pm 14$  (443 - 557) minutes. The intraoperative blood loss in the ECMO group  $(1728 \pm 734)$  tended to be greater than that in the control group  $(774 \pm 308)$ ; 175 176 however, the difference was not statistically significant (p = 0.36). In the control group, 1 patient (20.0%) intraoperatively required over 1,000 mL of blood transfusion of RBC. On the other hand, 177 3 patients (42.9%) were treated with over 1,000 mL of intraoperative blood transfusion of RBC 178 179 in the ECMO group. The mean amount of transfusion of RBC in the ECMO group  $(920 \pm 319)$ 180 tended to be greater than that in the control group  $(336 \pm 210)$ ; however, the difference was not 181 statistically significant (p = 0.28). In the control group, 1 patient (20.0%) needed over 1,000 mL 182 of fresh frozen plasma (FFP) transfusion. In the ECMO group, the requirement of FFP was over 183 1,000 mL in 2 patients (28,6%). No patient in the control group and 1 patient (14,3%) in the 184 ECMO group required intraoperative transfusion of platelet. Table 2 shows the inflow and 185 outflow cannula sizes in each case in the ECMO group. The cases with relatively smaller outflow

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 10

186 cannula (case #5 and 12) tended to require more transfusion products.

187

### 188 Intraoperative ADAMTS13 activity and vWF:Ag

189 Fig. 3A shows the comparisons of ADAMTS13 activity between the 2 groups in the 190 intraoperative period (before lung transplantation, before reperfusion, and at the end of surgery). 191 There was no significant difference in the ADAMTS13 activity between the ECMO and the 192 control group in the intraoperative period. Fig. 3B shows the comparisons of vWF:Ag between 193 the 2 groups in the intraoperative period. The level of vWF:Ag, representing a total amount of 194 vWF multimers, was expressed as its ratio to that in the standard human plasma because the 195 value of vWF: Ag varies significantly according to the age, ABO blood group, and so forth [18]. 196 There was no significant difference in vWF:Ag between the two groups during the intraoperative

197 period.

198

#### 199 Intraoperative vWF large multimer index

Fig. 4A shows the vWF large multimer index comparisons between the 2 groups in the 200 201 intraoperative period. The vWF large multimer index in the control group maintained a level 202 around 100% throughout the perioperative period (mean vWF large multimer index; before LT, 203  $76.7 \pm 10.0\%$ ; before reperfusion,  $100.1 \pm 10.9\%$ ; end of LT,  $112.6 \pm 10.6\%$ ). On the other hand, 204 the vWF large multimer index in the ECMO group decreased before reperfusion and at the end of 205 LT (mean vWF large multimer index; before LT,  $93.8 \pm 7.0\%$ ; before reperfusion,  $74.7 \pm 8.4\%$ ; end of LT,  $75.8 \pm 7.4\%$ ). The vWF large multimer index at the end of LT was significantly lower 206 207 in the ECMO group than that in the control group (p < 0.05). There were 3 patients who did not 208 receive intraoperative transfusion of FFP in the control group and the ECMO group, respectively.

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 11

209	In order to exclude the influence of FFP transfusion on the vWF large multimer indices, we
210	compared the indices in these patients. Fig. 4B shows each patient's intraoperative vWF large
211	multimer index without intraoperative FFP transfusion from the control and the ECMO group.
212	The vWF large multimer index of each case in the control group was 66.8%/86.6%/59.5% at
213	before LT, 89.0%/106.0%/59.5% before reperfusion, and, 89.0%/113.5%/147.7% at the end of
214	LT. The vWF large multimer index of each case in the ECMO group was 84.6%/85.9%/74.2%
215	before LT, 70.6%/65.5%/29.9% before reperfusion, and 92.3%/59.8%/41.8% at the end of LT.
216	Namely, intraoperative vWF large multimer indices decreased to as low as 30-40% in the ECMO
217	group without FFP transfusion whereas that in the control group was maintained at $> 60\%$ during
218	SLT surgery.

219

#### 220 **Postoperative characteristics and mortality**

Table 3 shows each group's postoperative 30-day, 90-day, and 1-year mortality. No patient was on ECMO at the intensive care unit upon arrival in the control group, and 2 patients (28.6%) were not weaned from VV ECMO in the ECMO group. There was no re-exploration thoracotomy for bleeding in either group. There was no mortality case in the control group within 1 year after transplantation. There was one 90-day mortality case in the ECMO group. The cause of the mortality was PGD.

227

## 228 **Discussion**

This is the first study that quantitatively analyzed the intraoperative changes in vWF large multimers in patients who underwent lung transplantation. We demonstrated that vWF large multimer index, which is regarded as the most reliable predictor of AvWS in recent years, was

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 12

lower in the patients who underwent VV ECMO support during SLT compared to those without
ECMO at the end of the surgery. However, the vWF large multimer index was maintained at >
75% in average at the end of SLT in the ECMO group, which did not significantly affect the
intra- and postoperative outcomes including blood loss, blood transfusion, and re-exploration
thoracotomy for bleeding.

237

238 In the present study, the ADAMTS13 activity and vWF:Ag showed no significant 239 change by intraoperative VV ECMO use. On the other hand, there was a significant decrease in 240 the vWF large multimer index at the end of the surgery in SLT. However, the mean vWF large 241 multimer index at the end of surgery was relatively maintained at 75.8% in the ECMO group. 242 The intraoperative blood loss and the required amounts of intraoperative transfusion products in 243 the ECMO group tended to be greater than those in the control group, but the difference was not 244 statistically significant. We previously reported a more severe decrease in the vWF large multimer index in 5 patients with acute cardiovascular diseases treated with VA ECMO [10]. 245 246 These patients exhibited vWF large multimer indices of 20.8% at 24 hours, 51.0% at 23 hours, 27.6% at 47 hours, 28.8% at 19 hours, and 31.0% at 82 hours after VA ECMO initiation [10], and 247 2 of the 5 patients had massive bleeding events, while the oozing type of bleeding at the skin of 248 249 the sites of cannula insertion was observed in all 5 patients, indicating an apparent hemostatic 250 disorder [10].

251

The results regarding AvWS in our study were also quite different from those in a previous study reported by Kalbhenn et al. They demonstrated that patients receiving VV ECMO support for respiratory failure were all diagnosed with AvWS, as shown by the ratio of the collagen-binding capacity (vWF:CB) to vWF:Ag decreasing to about 0.25 in average (vWF:CB/

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 13

256	vWF:Ag, normal: $> 0.7$ ). They also reported that 17 of the 18 patients developed bleeding
257	complications from 3 to 30 days after ECMO[14]. The different results in our study from those
258	in previous studies may be primarily explained by the short duration of time of ECMO use in our
259	study. The relatively low threshold for the use of intraoperative FFP transfusion in our cohort, the
260	thicker venous outflow cannulas in VV ECMO compared to those in VA ECMO in general [10],
261	and the lower blood flow rate of $1.5 - 2.5$ L/min in the present study compared with that in VA
262	ECMO used for patients with severe respiratory failure may also be responsible for the
263	difference.
264	
265	We acknowledge that there are several limitations in the present study. First, it was a
266	single-center analysis with a small number of patients, and thus we cannot accurately compare
267	the outcome of each group. Second, there were a few patients receiving an intraoperative
268	transfusion of FFP in both groups. Therefore, an accurate comparison of the vWF large multimer
269	indices was impossible. Whereas we compared the vWF large multimer indices in the patients
270	without intraoperative FFP transfusion between the control and the ECMO group, the number of
271	patients was not enough for statistical analysis. Third, we were not able to enroll a large enough
272	number of patients to undergo lung transplantation under CPB or VA ECMO in this study, which
273	would be a future challenges.
274	
275	In conclusion, intraoperative use of VV ECMO for SLT caused a decrease in the vWF
276	large multimer index. However, the vWF large multimer index in the present study remained at
277	an average of $> 75\%$ and was as low as 30–40% at the end of surgery with VV ECMO, and its

278 impact on bleeding complications was limited.

279

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 14

## 280 Acknowledgments

- 281 This research was supported by Japan Agency for Medical Research and Development
- under Grant Number 20ek0109370h0003. A part of this study was conducted as collaborative
- 283 research with Sysmex Corporation (Kobe, Japan).

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 15

### 284 **References**

- [1] Pena JJ, Bottiger BA, Miltiades AN. Perioperative Management of Bleeding and Transfusion
- for Lung Transplantation. Semin Cardiothorac Vasc Anesth 2020;24:74–83.
- [2] Diamond JM, Lee JC, Kawut SM, Shah RJ, Localio AR, Bellamy SL, et al. Clinical risk
- 288 factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med
- 289 2013;187:527–34.
- [3] Snyder LD, Wang Z, Chen DF, Reinsmoen NL, Finlen-Copeland CA, Davis WA, et al.
- 291 Implications for human leukocyte antigen antibodies after lung transplantation: A 10-year
- 292 experience in 441 patients. Chest 2013;144:226–33.
- [4] Lau CL, Palmer SM, Posther KE, Howell DN, Reinsmoen NL, Massey HT, et al. Influence of
- 294 Panel-Reactive Antibodies on Posttransplant Outcomes in Lung Transplant Recipients.
- 295 Transplantation 2000;69:1520–4.
- [5] Dalibon N, Geffroy A, Moutafis M, Vinatier I, Bonnette P, Stern M, et al. Use of
- 297 Cardiopulmonary Bypass for Lung Transplantation: A 10-Year Experience. J Cardiothorac Vasc
  298 Anesth 2006;20:668–72.
- 299 [6] Machuca TN, Collaud S, Mercier O, Cheung M, Cunningham V, Kim SJ, et al. Outcomes of
- 300 intraoperative extracorporeal membrane oxygenation versus cardiopulmonary bypass for lung
- transplantation. J Thorac Cardiovasc Surg 2015;149:1152–7.
- 302 [7] Magouliotis DE, Tasiopoulou VS, Svokos AA, Svokos KA, Zacharoulis D. Extracorporeal
- 303 membrane oxygenation versus cardiopulmonary bypass during lung transplantation: a meta-
- analysis. Gen Thorac Cardiovasc Surg 2018;66:38–47.
- 305 [8] Moreno Garijo J, Cypel M, McRae K, Machuca T, Cunningham V, Slinger P. The Evolving
- 306 Role of Extracorporeal Membrane Oxygenation in Lung Transplantation: Implications for

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 16

- 307 Anesthetic Management. J Cardiothorac Vasc Anesth 2019;33:1995–2006.
- 308 [9] Oishi H, Matsuda Y, Ejima Y, Toyama H, Hirama T, Watanabe T, et al. Changes in
- 309 haemodynamics during single lung transplantation under venovenous extracorporeal membrane
- 310 oxygenation. Interact Cardiovasc Thorac Surg 2022;35:ivac101.
- 311 [10] Tamura T, Horiuchi H, Obayashi Y, Fuki M, Imanaka M, Kuroda M, et al. Acquired von
- 312 Willebrand syndrome in patients treated with veno-arterial extracorporeal membrane
- 313 oxygenation. Cardiovasc Interv Ther 2019;358–63.
- 314 [11] Horiuchi H, Doman T, Kokame K, Saiki Y, Matsumoto M. Acquired von willebrand
- syndrome associated with cardiovascular diseases. J Atheroscler Thromb 2019;26:303–14.
- 316 [12] M Furlan, R Robles, M Solenthaler, M Wassmer, P Sandoz BL. Deficient Activity of von
- 317 Willebrand Factor-Cleaving Protease in Chronic Relapsing Thrombotic Thrombocytopenic
- 318 Purpura. Blood 1997;89:3097–103.
- 319 [13] Alsidawi S, Couto M, López-Candales A. Acquired Von Willebrand Syndrome In Aortic
- 320 Stenosis: Case Report And Review. Bol Asoc Med P R 2015;107:86–8.
- 321 [14] Kalbhenn J, Schmidt R, Nakamura L, Schelling J, Rosenfelder S, Zieger B. Early diagnosis
- 322 of Acquired von Willebrand Syndrome (AVWS) is elementary for clinical practice in patients
- treated with ECMO therapy. J Atheroscler Thromb 2015;22:265–71.
- 324 [15] Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic
- substrate for ADAMTS13 assay. Br J Haematol 2005;129:93–100.
- 326 [16] Tamura T, Horiuchi H, Imai M, Tada T, Shiomi H, Kuroda M, et al. Unexpectedly high
- 327 prevalence of acquired von Willebrand syndrome in patients with severe aortic stenosis as
- evaluated with a novel large multimer index. J Atheroscler Thromb 2015;22:1115–23.
- 329 [17] Sakatsume K, Saito K, Akiyama M, Sasaki K, Kawatsu S, Takahashi G, et al. Association
- between the severity of acquired von Willebrand syndrome and gastrointestinal bleeding after

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 17

- 331 continuous-flow left ventricular assist device implantation. Eur J Cardio-thoracic Surg
- 332 2018;54:841–6.
- 333 [18] Wang Z, Dou M, Du X, Ma L, Sun P, Cao H, et al. Influences of ABO blood group, age and
- 334 gender on plasma coagulation factor VIII, fibrinogen, von Willebrand factor and ADAMTS13
- levels in a Chinese population. PeerJ 2017;2017.

336

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 18

## 337 **Tables**

#### 338 Table 1. Pretransplant demographics

#### 339

	Control group	ECMO <sup>a</sup> group	P value
	(n = 5)	(n = 7)	1 value
Age (years)	$48.4 \pm 3.8 (34 - 57)$	47.1 ± 4.1 (23 – 59)	0.85
Gender (M/F)	3 / 2	4 / 3	0.92
Height (cm)	$164.4 \pm 3.2 (153.5 - 175.0)$	$162.4 \pm 2.6 (150.4 - 173.0)$	0.66
Weight (kg)	$50.5 \pm 6.4 (35.0 - 75.0)$	$55.6 \pm 6.9 (30.0 - 91.8)$	0.64
BMI $(kg/m^2)^{b}$	$18.5 \pm 2.0 (13.0 - 26.4)$	$20.7 \pm 2.0 (13.3 - 30.7)$	0.50
Indication			
IPF <sup>c</sup>	0 (0%)	4 (57.1%)	
COPD <sup>d</sup>	3 (60.0%)	0 (0%)	
LAM <sup>e</sup>	1 (20.0%)	2 (28.6%)	
CTD-ILD <sup>f</sup>	1 (20.0%)	1 (14.3%)	
Pulmonary function test			
FVC <sup>g</sup> (% predicted)	$55.1 \pm 5.0 (46.4 - 76.0)$	$50.9 \pm 8.0 (23.6 - 85.0)$	0.71
FEV1 <sup>h</sup> (% predicted)	$35.1 \pm 7.5 (17.8 - 57.6)$	$43.7 \pm 6.5 (26.3 - 78.4)$	0.44
PT-INR <sup>i</sup>	$0.99 \pm 0.02 \ (0.93 - 1.04)$	$1.00 \pm 0.02 \ (0.99 - 1.00)$	0.79
APTT <sup>j</sup> (sec)	$32.2 \pm 2.7 (27.4 - 33.9)$	$30.3 \pm 1.0 (27.4 - 33.9)$	0.53
Platelet count (x $10^{3}/\mu$ l)	$258 \pm 12 (221 - 301)$	$240 \pm 13 (189 - 282)$	0.39

Values are expressed as mean ± standard error (range) or number (%). <sup>a</sup> ECMO, extracorporeal membrane oxygenation (ECMO). <sup>b</sup> BMI, body mass index. <sup>c</sup> IPF, idiopathic pulmonary fibrosis. <sup>d</sup> COPD, chronic obstructive pulmonary. <sup>e</sup> LAM, lymphangioleiomyomatosis. <sup>f</sup> CTD-ILD, connective tissue disease-associated interstitial lung disease. <sup>g</sup> FVC, forced vital capacity. <sup>h</sup> FEV1, forced expiratory volume in one second. <sup>i</sup> PT-INR, prothrombin time–international normalized ratio. <sup>j</sup> APTT, activated partial thromboplastin time.

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 19

#### 341 **Table 2. Operative characteristics**

#### 342

Case #	Group	OP <sup>a</sup> time (min)	CIT <sup>b</sup> (min)	Intra-OP ECMO time <sup>c</sup> (min)	Cannula size (Fr)		Intra-OP	Pleural	Intra-OP blood transfusion		
					Inflow	Outflow	blood loss (mL)	adhesion grade <sup>f</sup>	RBC <sup>c</sup> (mL)	FFP <sup>d</sup> (mL)	Platelet (mL)
4	Control	365	361	-	-	-	249	None	0	0	0
6	Control	383	456	-	-	-	644	Severe	280	480	0
7	Control	366	457	-	-	-	307	None	0	0	0
8	Control	452	480	-	-	-	2122	Severe	1400	1200	0
9	Control	430	564	-	-	-	550	Moderate	280	0	0
1	ECMO	504	457	459	22	22	2332	None	1680	2880	0
2	ECMO	423	453	517	19.5	18	547	Moderate	280	0	0
3	ECMO	356	447	455	21	21	869	None	560	480	0
5	ECMO	482	656	557	21	15	6228	Severe	1960	1440	200
10	ECMO	380	457	443	21	16.5	748	Mild	0	0	0
11	ECMO	409	550	485	21	16.5	177	None	0	0	0
12	ECMO	468	539	492	16.5	15	1198	None	1960	480	0
		P = 0.29	P = 0.34				P = 0.36		P = 0.28	P = 0.44	

<sup>a</sup> OP, operative. <sup>b</sup> CIT, cold ischemia time. <sup>c</sup> ECMO, extracorporeal membrane oxygenation (ECMO). <sup>d</sup> RBC, red blood cell. <sup>e</sup> FFP, fresh frozen plasma. f Pleural adhesion grade: severe, 50% to whole thoracic cavity; moderate, partial (only band adhesions) to < 50%; mild, no to partial adhesion; none, no adhesion.

343

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 20

#### 344 Table 3. Postoperative characteristics and mortality

345

	Control group	ECMO <sup>a</sup> group
	(n = 5)	(n = 7)
ECMO on ICU <sup>b</sup> arrival	0 (0%)	2 (28.6%)
Re-exploration thoracotomy for bleeding	0 (0%)	0 (0%)
Mortality		
30-day	0 (0%)	0 (0%)
90-day	0 (0%)	1 (14.3%) <sup>b</sup>
1-year	0 (0%)	0 (0%)

Values are expressed as numbers (%). <sup>a</sup> ECMO, extracorporeal membrane oxygenation. <sup>b</sup> ICU, intensive care unit. <sup>c</sup> The cause of death was primary graft dysfunction.

346

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 21

## 347 Figure legends

#### 348 Figure 1. Flow diagram for study participation

349 SLT, single lung transplantation; VA ECMO, venoarterial extracorporeal membrane
 350 oxygenation; VV ECMO, venovenous extracorporeal membrane oxygenation.

351

# Figure 2. Quantification method for calculation of the von Willebrand factor (vWF) large multimer index

We first determined the concentrations of von Willebrand factor (vWF) in the standard 354 355 human plasma (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany) and in 356 each sample simultaneously by western blot analysis under reduced conditions followed by 357 densitometry analysis. Bands 1–5 (starting from the lowest molecular weight band) were 358 classified as low, 6-10 as medium, and those >10 as large multimers. The vWF large multimer proportion was calculated as the densitometric area of those bands. The vWF large multimer 359 index (%) was defined as the ratio of the large multimer proportion in the total vWF (vWF large 360 multimer ratio) derived from a sample to that from the standard human plasma in the adjacent 361 362 lane.

363

#### 364 Figure 3. Intraoperative ADAMTS13 activity and von Willebrand factor antigen (vWF:Ag)

For intraoperative analysis, blood samples were collected from the patients immidiately before lung transplantation, before reperfusion (immediately before reperfusion of the lung graft), and at the end of surgery. These time points are indicated as "Before LT," "Before reperfusion," and "End of LT," respectively (LT, lung transplantation). The data are represented as a box and whiskers plot. White boxes represent the control group (n = 5, white boxes with stripes for

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

370	ADAMTS13 activity, white boxes with dots for vWF:Ag), and gray boxes are the extracorporeal
371	membrane oxygenation (ECMO) group ( $n = 7$ , gray boxes with stripes for ADAMTS13 activity,
372	gray boxes with dots for vWF:Ag). The middle horizontal line represents the median. The upper
373	and lower borders of the box represent the upper and lower quartiles. The upper and lower
374	whiskers represent the maximum and minimum values.
375	(A) Intraoperative ADAMTS13 activity. There was no significant difference in the ADAMTS13
376	activity between the control and ECMO group in the perioperative period. The mean
377	ADAMTS13 activity before LT (control group vs. ECMO group), $41.6 \pm 8.2\%$ vs. $45.2 \pm 10.1\%$ ,
378	$p > 0.05$ ; before reperfusion, (control group vs. ECMO group), $37.6 \pm 8.0\%$ vs. $41.7 \pm 9.3\%$ , $p > 1.0\%$
379	0.05; at the end of LT, (control group vs. ECMO group), $35.3 \pm 5.5\%$ vs. $47.4 \pm 8.5\%$ , $p > 0.05$ .
380	(B) Intraoperative vWF:Ag. There was no significant difference in the vWF:Ag between the
381	control and ECMO group in the intraoperative period. The mean vWF:Ag activity at before LT
382	(control group vs. ECMO group), $114.4 \pm 40.1\%$ vs. $181.2 \pm 42.8\%$ , $p > 0.05$ ; before reperfusion,
383	(control group vs. ECMO group), $157.5 \pm 34.1\%$ vs. $136.9 \pm 27.9\%$ , $p > 0.05$ ; at the end of LT,
384	(control group vs. ECMO group), $158.9 \pm 37.0\%$ vs. $137.0 \pm 25.4\%$ , $p > 0.05$ .
385	
386	Figure 4 Intraoperative von Willebrand factor (vWF) large multimer index

#### ure 4. Intraoperative von Willebrand factor (vWF) large multimer index 380

387 For intraoperative analysis, blood samples were collected from the patients right before lung transplantation, before reperfusion (immediately before reperfusion of the lung graft), and at 388 the end of surgery. These time points are indicated as "Before LT," " Before reperfusion," and 389 390 "End of LT," respectively (LT, lung transplantation).

391 (A) Intraoperative vWF large multimer index. The data are represented as a box and whiskers

- plot. White boxes represent the control group (n = 5), and gray boxes are the extracorporeal 392
- 393 membrane oxygenation (ECMO) group (n = 7). The middle horizontal line represents the median.

Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

Hisashi Oishi, page 23

- 394 The upper and lower borders of the box represent the upper and lower quartiles. The upper and
- 395 lower whiskers represent the maximum and minimum values. The mean von Willebrand factor
- 396 (vWF) large multimer index at before LT (control group vs. ECMO group),  $76.7 \pm 10.0\%$  vs.
- $93.8 \pm 7.0\%$ , p > 0.05; at before reperfusion, (control group vs. ECMO group),  $100.1 \pm 10.9\%$  vs.
- 398 74.7  $\pm$  8.4%, p > 0.05; at end of LT, (control group vs. ECMO group), 112.6  $\pm$  10.6% vs. 75.8  $\pm$
- 399 7.4%, *p* < 0.05.
- 400 (B) Intraoperative vWF large multimer index: comparison between the cases without fresh frozen
- 401 plasma (FFP) transfusion. There were 3 patients in the control group and the ECMO group,
- 402 respectively who did not receive intraoperative transfusion of FFP. The vWF large multimer
- 403 index of each case in the control group was 66.8%/86.6%/59.5% before LT,
- 404 89.0%/106.0%/59.5% before reperfusion, and, 89.0%/113.5%/147.7% at the end of LT. The vWF
- 405 large multimer index of each case in the ECMO group was 84.6%/85.9%/74.2% before LT,
- 406 70.6%/65.5%/29.9% before reperfusion, and 92.3%/59.8%/41.8% at the end of LT.

## Figure 1



medRxiv preprint doi: https://doi.org/10.1101/2023.02.07.23285614; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

## Figure 2



Figure 3







Before LT Before reperfusion End of LT